So, co-inhibiting MAPK and PI3K pathways can entirely control malignant behavior of cell lines having double mutation of these two pathways, providing a strong reason to target these pathogenic pathways jointly in the treatment of thyroid cancer (37). Here, PIK3CG is linked to thyroid gland carcinoma.